N
OGEN icon

Natixis’s Oragenics OGEN Stock Holding History

Natixis’s Portfolio OGEN Stock Details OGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1
Closed -$34K – 508
2014
Q1 		$34K Buy
+1
New +$60.7K ﹤0.01% 506

Other funds holding OGEN

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EEG
E.E. Geduld $178M AUM 29.34% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Natixis's OGEN Position: Q2 2014 in Review

Natixis sold out of Oragenics (OGEN) in Q2 2014, closing a stake of 1 share — an estimated $34K sold.

Natixis first reported a position in OGEN in Q1 2014 and held it in 1 quarter. The position peaked at $34K in Q1 2014. 8 funds tracked by Wall St. Rank hold OGEN as of Q2 2014.

  • Natixis reported no remaining Oragenics position as of Q2 2014 after selling out during the quarter.
  • Natixis sold 1 Oragenics share in Q2 2014, an estimated $34K.
  • Natixis first reported a position in Oragenics in Q1 2014 and held it in 1 quarter.
  • Natixis's Oragenics position peaked at $34K in Q1 2014.
  • 8 funds tracked by Wall St. Rank held Oragenics as of Q2 2014.

Based on Natixis's 13F filing for Q2 2014, filed 14 Aug 2014.